Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

BACKGROUND: Patients with ALK‐rearranged non‐small cell lung cancer (ALK+ NSCLC) inevitably acquire resistance to ALK inhibitors. Longitudinal monitoring of cell‐free plasma DNA (cfDNA) next‐generation sequencing (NGS) could predict the response and resistance to tyrosine kinase inhibitor (TKI) ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Minsuk, Ku, Bo mi, Olsen, Steve, Park, Sehhoon, Lefterova, Martina, Odegaard, Justin, Jung, Hyun‐Ae, Sun, Jong‐Mu, Lee, Se‐Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung‐Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359877/
https://www.ncbi.nlm.nih.gov/pubmed/35437925
http://dx.doi.org/10.1002/cam4.4663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359877/
https://www.ncbi.nlm.nih.gov/pubmed/35437925
http://dx.doi.org/10.1002/cam4.4663

Ejemplares similares